Moderna receives health canada authorization for second omicron-targeting bivalent booster

Mrna-1273.222 targets ba.4/ba.5 omicron subvariants and follows the approval of mrna-1273.214 (spikevax bivalent) in canada, which targets the omicron ba.1 subvariant cambridge, ma / accesswire / november 4, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced health canada has authorized the use of its ba.4/ba.5 omicron-targeting bivalent covid-19 booster vaccine, mrna-1273.222, as a booster dose for active immunization against covid-19 caused by the sars-cov-2 virus in individuals 18 years of age and older. the 50 Μg booster dose of mrna-1273.222 includes 25 Μg of mrna encoding for the spike protein of ba.4/ba.5 and 25 Μg encoding for the original strain of the sars-cov-2 virus.
MRNA Ratings Summary
MRNA Quant Ranking